IPO - ADC Therapeutics SA

Form Type: S-3

Filing Date: 2025-06-30

Corporate Action: Ipo

Type: New

Accession Number: 000095010325008153

Filing Summary: ADC Therapeutics SA has filed a registration statement on Form S-3 with the SEC for the resale of 27,726,052 common shares. The filing comes after the company engaged in a $100 million private placement of its securities on June 11, 2025, which included 13,031,161 common shares sold at a price of $3.53 per share and pre-funded warrants for 15,734,267 common shares at an effective price of $3.432 per warrant. The private placement closed on June 16, 2025. This prospectus allows selling shareholders to offer the shares at various market prices or negotiated prices. ADC Therapeutics indicates it will not receive proceeds from the sale unless the pre-funded warrants are exercised in cash, potentially yielding up to CHF 1,258,741.36 for working capital and general corporate purposes. The company’s common shares are traded on the NYSE under the symbol 'ADCT'.